

**Research Compliance Activity and Turn-Around-Time (TAT) Summary Report**  
**Fiscal Year 2022 (7/1/2021 to 6/30/2022)**

*TAT calculated from submission date to date of approval. TAT not calculated for continuing reviews.*

<b>Institutional Biosafety Committee (IBC) - IUPUI</b>								
	Q1 TAT		Q2 TAT		Q3 TAT		Q4 TAT	
	Mean	Median	Mean	Median	Mean	Median	Mean	Median
<b>Full Board</b>								
New Studies - Full Board (to review)	28.4	21.5	29.0	28.0	28.4	24.0		
New Studies - Full Board (to approval)	40.8	35.5	48.5	55.0	38.9	39.0		
<b>Exempt</b>								
New Studies - Exempt (to determination)	13.6	18.0	19.3	20.5	25.5	15.5		
<b>Amendments</b>								
Amendments - Minor	4.6	1.0	3.9	2.0	4.4	1.0		
Amendments - Major	21.9	21.0	18.2	15.0	19.4	19.0		

Area Activities/Throughput (T)	Q1 (Jul-Sep)			Q2 (Oct-Dec)			Q3 (Jan-Mar)			Q4 (Apr-Jun)		
	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged
New Studies - Full Board	11	12	1	13	11	-2 (15.4%)	15	16	1			
New Studies - Exempt	17	9	-8 (47.1%)	10	11	1	9	8	-1 (11.1%)			
Amendments - Minor	154	140	-14 (9.1%)	145	142	-3 (2.1%)	145	155	10			
Amendments - Major	24	25	1	17	18	1	23	21	-2 (8.7%)			
Continuing Reviews	83	75	-8 (9.6%)	85	87	2	89	93	4			
<b>TOTAL</b>	<b>289</b>	<b>261</b>	<b>-28 (9.7%)</b>	<b>270</b>	<b>269</b>	<b>-1 (0.4%)</b>	<b>281</b>	<b>293</b>	<b>12 (-4.3%)</b>	<b>0</b>	<b>0</b>	

Area Training Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Presentations (# of events)	0	0	1		1

Reportable Events/Activities	Q1 (Jul-Sep)	Q2 (Oct-Dec)	Q3 (Jan-Mar)	Q4 (Apr-Jun)	FY TOTALS
Immediate OBA Report	0	0	0		0
30 Day OBA Report	0	0	1		1
Lab Accident/Injury/Exposure	0	1	0		1

Reporting Agency: NIH Office of Biotechnology Activities (OBA)